Top

Published in:

01-12-2008 | Clinical Trial

Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases

Authors: Michael Braun, Uta Flucke, Manuel Debald, Gisela Walgenbach-Bruenagel, Klaus-Jürgen Walgenbach, Tobias Höller, Martin Pölcher, Matthias Wolfgarten, Axel Sauerwald, Mignon Keyver-Paik, Marietta Kühr, Reinhard Büttner, Walther Kuhn

Published in: Breast Cancer Research and Treatment | Issue 3/2008

Abstract

Purpose The aim of this study was to investigate the use of D2-40 for the detection of lymphovascular invasion (LVI) in node positive and negative early breast cancer. LVI is associated with axillary lymph node metastases (ALNM) and a long-term prognostic factor. A precise identification of LVI would have a strong clinical impact for breast cancer patients. Methods Immunohistochemical staining with D2-40 and CD34 was performed on formalin-fixed, paraffin-embedded tissue sections of 254 invasive breast tumors of 247 patients with node negative and node positive early breast cancer. All slides were screened for the presence of LVI. Correlation with clinico-pathological factors including LVI as retrieved by routine haematoxylin and eosin (H.E.) stained sections and the eligibility for the prediction of ALNM was assessed. Results Using the D2-40 antibody for immunostaining, our results demonstrate a significant higher detection (P < 0.001) of LVI as compared with routine H.E.-staining in early breast cancer. LVI was correctly identified by D2-40 (D2-40+) in 70 out of 254 tumors (28%) as compared to 40 tumors (16%) by routine HE staining (HE+). There was a significant correlation between D2-40 + LVI and age, t-stage, nodal status, grading and hormonreceptor-status. Correlation between D2-40 + LVI and menopausal-status, HER2-status and histological type was not significant, while there was a significant correlation of D2-40 and so called “triple negative” tumors (ER/PR and HER2neu-negative). In a multivariate analysis D2-40+ was the strongest predictor for ALNM with an odds ratio of 3.489 and a P-value of P = 0.0003, followed only by T-stage and grading with odds ratios of 3.167 and 1.953 and P-values P = 0.0003 and P = 0.0352. Conclusion Immunostaining with D2-40 significantly increased the frequency of detection of lymphatic invasion compared to conventional H.E.-staining in early breast cancer. As LVI is a strong predictive and prognostic marker, the monoclonal antibody D2-40 has the potential to play a significant role in pathological routine workup of breast tumors. Further prospective studies are needed to prove the clinical impact of D2-40.

Jemal A et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56(2):106–130PubMedCrossRef

Glissmeyer M (2007) Reviewing prognostic factors in breast cancer management. Jaapa 20(5):42–46PubMed

Mirza AN et al (2002) Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg 235(1):10–26PubMedCrossRef

Rosen PP et al (1989) Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 7(9):1239–1251PubMed

Lee AK et al (1990) Prognostic significance of peritumoral lymphatic and blood vessel invasion in node-negative carcinoma of the breast. J Clin Oncol 8(9):1457–1465PubMed

Lauria R et al (1995) The prognostic value of lymphatic and blood vessel invasion in operable breast cancer. Cancer 76(10):1772–1778PubMedCrossRef

Pinder SE et al (1994) Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long-term follow-up. Histopathology 24(1):41–47PubMedCrossRef

Rosen PP et al (1993) Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 11(11):2090–2100PubMed

Fitzgibbons PL et al (2000) Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7):966–978PubMed

10.

Hasebe T et al (2004) Histological characteristics of tumor in vessels and lymph nodes are significant predictors of progression of invasive ductal carcinoma of the breast: a prospective study. Hum Pathol 35(3):298–308PubMedCrossRef

11.

Kato T et al (2003) The combination of angiogenesis and blood vessel invasion as a prognostic indicator in primary breast cancer. Br J Cancer 88(12):1900–1908PubMedCrossRef

12.

Shoup M et al (1999) Predictors of axillary lymph node metastases in T1 breast carcinoma. Am Surg 65(8):748–752; discussion 752–753

13.

Chua B et al (2001) Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg 71(12):723–728PubMedCrossRef

14.

Neville AM et al (1992) Factors predicting treatment responsiveness and prognosis in node-negative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10(5):696–705PubMed

15.

Van den Eynden GG et al (2006) Distinguishing blood and lymph vessel invasion in breast cancer: a prospective immunohistochemical study. Br J Cancer 94(11):1643–1649PubMed

16.

Obermair A et al (1995) Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival. Int J Cancer 62(2):126–131PubMedCrossRef

17.

Weninger W et al (1999) Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi’s sarcoma tumor cells. Lab Invest 79(2):243–251PubMed

18.

Breiteneder-Geleff S et al (1999) Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 154(2):385–394PubMed

19.

Birner P et al (2001) Lymphatic microvessel density as a novel prognostic factor in early-stage invasive cervical cancer. Int J Cancer 95(1):29–33PubMedCrossRef

20.

Birner P et al (2001) Selective immunohistochemical staining of blood and lymphatic vessels reveals independent prognostic influence of blood and lymphatic vessel invasion in early-stage cervical cancer. Clin Cancer Res 7(1):93–97PubMed

21.

Birner P et al (2000) Lymphatic microvessel density in epithelial ovarian cancer: its impact on prognosis. Anticancer Res 20(5A):2981–2985PubMed

22.

Partanen TA, Alitalo K, Miettinen M (1999) Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 86(11):2406–2412PubMedCrossRef

23.

Schacht V et al (2005) Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 166(3):913–921PubMed

24.

Kahn HJ, Marks A (2002) A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 82(9):1255–1257PubMed

25.

Remmele W, Stegner HE (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8(3):138–140PubMed

26.

Gombos Z et al (2005) Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix. Clin Cancer Res 11(23):8364–8371PubMedCrossRef

27.

Walgenbach-Bruenagel G et al (2006) Detection of lymphatic invasion in early stage primary colorectal cancer with the monoclonal antibody D2-40. Eur Surg Res 38(5):438–444PubMedCrossRef

28.

Fukunaga M (2005) Expression of D2-40 in lymphatic endothelium of normal tissues and in vascular tumours. Histopathology 46(4):396–402PubMedCrossRef

29.

Arnaout-Alkarain A et al (2007) Significance of lymph vessel invasion identified by the endothelial lymphatic marker D2-40 in node negative breast cancer. Mod Pathol 20(2):183–191PubMedCrossRef

30.

Choi WW et al (2005) Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod Pathol 18(1):143–152PubMedCrossRef

31.

Van der Auwera I et al (2005) Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study. Clin Cancer Res 11(21):7637–7642PubMedCrossRef

32.

Van der Auwera I et al (2004) Increased angiogenesis and lymphangiogenesis in inflammatory versus noninflammatory breast cancer by real-time reverse transcriptase-PCR gene expression quantification. Clin Cancer Res 10(23):7965–7971PubMedCrossRef

33.

Nime FA et al (1977) Prognostic significance of tumor emboli in intramammary lymphatics in patients with mammary carcinoma. Am J Surg Pathol 1(1):25–30PubMedCrossRef

34.

Goldhirsch A et al (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16(10):1569–1583PubMedCrossRef

35.

Goldhirsch A et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18(7):1133–1144PubMedCrossRef

36.

Pantel K, Brakenhoff RH (2004) Dissecting the metastatic cascade. Nat Rev Cancer 4(6):448–456PubMedCrossRef

37.

Evangelou E, Kyzas PA, Trikalinos TA (2005) Comparison of the diagnostic accuracy of lymphatic endothelium markers: Bayesian approach. Mod Pathol 18(11):1490–1497PubMedCrossRef

38.

Saigo PE, Rosen PP (1987) The application of immunohistochemical stains to identify endothelial-lined channels in mammary carcinoma. Cancer 59(1):51–54PubMedCrossRef

39.

Lee AK, DeLellis RA, Wolfe HJ (1986) Intramammary lymphatic invasion in breast carcinomas. Evaluation using ABH isoantigens as endothelial markers. Am J Surg Pathol 10(9):589–594PubMedCrossRef

40.

Acs G et al (2007) Extensive retraction artifact correlates with lymphatic invasion and nodal metastases and predicts poor outcome in early stage breast carcinoma. Am J Surg Pathol 31(1):129–140PubMedCrossRef

41.

Irie J et al (2007) Artefact as the pathologist's friend: peritumoral retraction in in situ and infiltrating duct carcinoma of the breast. Int J Surg Pathol 15(1):53–59PubMedCrossRef

42.

Tezuka K et al (2007) Prognostic significance of lymphovascular invasion diagnosed by lymphatic endothelium immunostaining in breast cancer patients. Oncol Rep 17(5):997–1003PubMed

43.

Dent R et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13(15 Pt 1):4429–4434PubMedCrossRef

44.

Russo J et al (1987) Predictors of recurrence and survival of patients with breast cancer. Am J Clin Pathol 88(2):123–131PubMed

45.

Fisher B et al (1983) Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 52(9):1551–1557PubMedCrossRef

46.

Karlsson P et al (2007) The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. J Clin Oncol 25(15):2019–2026PubMedCrossRef

47.

Cody HS 3rd, Borgen PI, Tan LK (2004) Redefining prognosis in node-negative breast cancer: can sentinel lymph node biopsy raise the threshold for systemic adjuvant therapy? Ann Surg Oncol 11(3 Suppl):227S–230SPubMed

48.

Rivadeneira DE et al (2000) Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg 191(1):1–6; discussion 6–8

49.

Anan K et al (2000) Axillary lymph node metastases in patients with small carcinomas of the breast: is accurate prediction possible? Eur J Surg 166(8):610–615PubMedCrossRef

50.

O'Rourke S et al (1994) Local recurrence after simple mastectomy. Br J Surg 81(3):386–389PubMedCrossRef

51.

EBCTCG (2000) Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 355(9217):1757–1770

52.

Wallgren A et al (2003) Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group trials I through VII. J Clin Oncol 21(7):1205–1213PubMedCrossRef

53.

Clarke M et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 366(9503):2087–2106PubMed

Title: Detection of lymphovascular invasion in early breast cancer by D2-40 (podoplanin): a clinically useful predictor for axillary lymph node metastases
Authors: Michael Braun
Uta Flucke
Manuel Debald
Gisela Walgenbach-Bruenagel
Klaus-Jürgen Walgenbach
Tobias Höller
Martin Pölcher
Matthias Wolfgarten
Axel Sauerwald
Mignon Keyver-Paik
Marietta Kühr
Reinhard Büttner
Walther Kuhn
Publication date: 01-12-2008
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 3/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-007-9875-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2008

HER2 in well differentiated breast cancer: is testing necessary?

Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis

Feasibility of two dose-dense FEC regimens with growth factor support for adjuvant therapy in patients with early breast cancer: results from a randomised study of the Central European Cooperative Oncology Group (CECOG)

Disruption of ERα signalling pathway by PPARγ agonists: evidences of PPARγ-independent events in two hormone-dependent breast cancer cell lines

Is face-only photographic view enough for the aesthetic evaluation of breast cancer conservative treatment?

The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer